CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464600503
- Phone
- 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- SC 13G/A Stake Amended Statement of Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Option exercise Co-Chief Executive Officer acquired 63,690 shares (option exercise)
- SC 13G Stake Amended Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
- 8-K Event Other events
- 4 Open-market sale Co-Chief Executive Officer sold 18,589 shares at $3.20 ($59,429)
- 4 Open-market sale Co-Chief Executive Officer sold 18,589 shares at $3.20 ($59,414)
- 4 Open-market sale Chief Medical Officer sold 11,442 shares at $3.20 ($36,559)
- 4 Open-market sale Chief Legal Officer sold 8,709 shares at $3.20 ($27,840)
- 4 Option exercise Co-Chief Executive Officer acquired 1,857 shares (option exercise)
- 4 Option exercise Co-Chief Executive Officer acquired 34,449 shares (option exercise)
- 4 Open-market buy Chief Financial Officer bought 40,000 shares at $2.53 ($101,368)
- 4 Open-market buy Director bought 50,000 shares at $2.13 ($106,590)
- 4/A Option exercise Chief Financial Officer acquired 18,165 shares (option exercise)
- 4 Open-market buy Director bought 100,000 shares at $2.20 ($219,800)
- SC 13G Stake Amended Statement of Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
Page 10 of 23 · 446 filings